Pancreatic β-cell imaging in humans: Fiction or option?

Diabetes, Obesity and Metabolism

Volumn 18, Issue 1, 2016, Pages 6-15

  Laurent, D ^a   Vinet, L ^b   Lamprianou, S ^b   Daval, M ^c   Filhoulaud, G ^c   Ktorza, A ^c   Wang, H ^d   Sewing, S ^d   Juretschke, H P ^e   Glombik, H ^e   Meda, P ^b   Boisgard, R ^f   Nguyen, D L ^f   Stasiuk, G J ^g   Long, N J ^g   Montet, X ^h   Hecht, P ⁱ   Kramer, W ^j   Rutter, G A ^k   Hecksher Sorensen J ^l  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^f DIF   (France)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ IMIDIA Project Office   (Austria)

^j Scientific Consultant for Sanofi Deutschland GmbH   (Germany)

^k HAMMERSMITH HOSPITAL   (United Kingdom)

^l NOVO NORDISK A S   (Denmark)

more..

Author keywords

Beta cell; GLP 1 analogue; Islets; Sulphonylureas; Type 1 diabetes; VMAT2

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; MANGANESE; MEMBRANE PROTEIN; SULFONYLUREA RECEPTOR; TMEM27 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER; ZINC;

BIOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG INDUSTRY; HEALTH CARE; HUMAN; HUMAN CELL; IMMUNE MEDIATED INJURY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ADULT; ANIMAL; CELL ADHESION; DIABETES MELLITUS; LUMINESCENCE; METABOLISM; MOLECULAR IMAGING; MOUSE; PATHOLOGY; PROCEDURES; RAT;

ADULT; ANIMALS; CELL ADHESION; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INSULIN-SECRETING CELLS; LUMINESCENT MEASUREMENTS; MANGANESE; MEMBRANE GLYCOPROTEINS; MICE; MOLECULAR IMAGING; RATS; SULFONYLUREA RECEPTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS; ZINC;

EID: 84955191267     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12544     Document Type: Review

References (109)

1. Scully T. Diabetes in numbers. Nature 2012; 485: S2-3.
2. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10(Suppl. 4): 32-42.
3. Butler AE, Janson J, Soeller WC, Butler PC. Increased -cell apoptosis prevents adaptive increase in -cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003; 52: 2304-2314.
4. Rutter G, Parton L. The beta-cell in type 2 diabetes and in obesity. Obes Metab 2008; 36: 118-134.
5. Kulkarni RN, Mizrachi EB, Ocana AG, Stewart AF. Human beta-cell proliferation and intracellular signaling: driving in the dark without a road map. Diabetes 2012; 61: 2205-2213.
6. Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell 2013; 153: 747-758.
7. Bouwens L, Rooman I. Regulation of pancreatic beta-cell mass. Physiol Rev 2005; 85: 1255-1270.
8. Ackermann AM, Gannon M. Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion. J Mol Endocrinol 2007; 38: 193-206.
9. Goldman M. Reflections on the innovative medicines initiative. Nat Rev Drug Discov 2011; 10: 321-322.
10. Goldman M, Seigneuret N, Eichler HG. The innovative medicines initiative: an engine for regulatory science. Nat Rev Drug Discov 2015; 14: 1-2.
11. IMI. 2015. Available from URL: http://www.imi.europa.eu. Accessed 2 July 2015.
12. IMIDIA. 2015. Available from URL: http://www.imidia.org. Accessed 2 July 2015.
13. Yang L, Ji W, Xue Y, Chen L. Imaging beta-cell mass and function in situ and in vivo. J Mol Med (Berl) 2013; 91: 929-938.
14. Blomberg BA, Codreanu I, Cheng G, Werner TJ, Alavi A. Beta-cell imaging: call for evidence-based and scientific approach. Mol Imaging Biol 2013; 15: 123-130.
15. Di Gialleonardo V, de Vries EF, Di Girolamo M etal. Imaging of beta-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus. Endocr Rev 2012; 33: 892-919.
16. Malaisse WJ, Maedler K. Imaging of the beta-cells of the islets of Langerhans. Diabetes Res Clin Pract 2012; 98: 11-18.
17. Andralojc K, Srinivas M, Brom M etal. Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis. Diabetologia 2012; 55: 1247-1257.
18. Thorel F, Nepote V, Avril I etal. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010; 464: 1149-1154.
19. Chera S, Baronnier D, Ghila L etal. Diabetes recovery by age-dependent conversion of pancreatic delta-cells into insulin producers. Nature 2014; 514: 503-507.
20. Agdeppa ED, Spilker ME. A review of imaging agent development. AAPS J 2009; 11: 286-299.
21. ICH Guidelines. 2009. Available from URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf. Accessed 26 August.
22. Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Krohn KA. Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther 2004; 6: 652-659.
23. Sweet IR, Cook DL, Lernmark A etal. Systematic screening of potential beta-cell imaging agents. Biochem Biophys Res Commun 2004; 314: 976-983.
24. Greer LF III, Szalay AA. Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence 2002; 17: 43-74.
25. Sato A, Klaunberg B, Tolwani R. In vivo bioluminescence imaging. Comp Med 2004; 54: 631-634.
26. Contag CH, Spilman SD, Contag PR etal. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol 1997; 66: 523-531.
27. Virostko J, Radhika A, Poffenberger G etal. Bioluminescence imaging in mouse models quantifies beta cell mass in the pancreas and after islet transplantation. Mol Imaging Biol 2010; 12: 42-53.
28. Smith SJ, Zhang H, Clermont AO etal. In vivo monitoring of pancreatic beta-cells in a transgenic mouse model. Mol Imaging 2006; 5: 65-75.
29. Sever D, Eldor R, Sadoun G etal. Evaluation of impaired beta-cell function in nonobese-diabetic (NOD) mouse model using bioluminescence imaging. FASEB J 2011; 25: 676-684.
30. Virostko J, Radhika A, Poffenberger G etal. Bioluminescence imaging reveals dynamics of beta cell loss in the non-obese diabetic (NOD) mouse model. PLoS One 2013; 8: e57784.
31. Patel M, Gleason A, O'Malley S etal. Non-invasive bioluminescence imaging of beta-cell function in obese-hyperglycemic [ob/ob] mice. PLoS One 2014; 9: e106693.
32. Virostko J, Chen Z, Fowler M etal. Factors influencing quantification of in vivo bioluminescence imaging: application to assessment of pancreatic islet transplants. Mol Imaging 2004; 3: 333-342.
33. Virostko J, Henske J, Vinet L etal. Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands. Proc Natl Acad Sci U S A 2011; 108: 20719-20724.
34. Balla DZ, Gottschalk S, Shajan G etal. In vivo visualization of single native pancreatic islets in the mouse. Contrast Media Mol Imaging 2013; 8: 495-504.
35. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 2009; 50: 2-5.
36. Altirriba J, Gasa R, Casas S etal. The role of transmembrane protein 27 (TMEM27) in islet physiology and its potential use as a beta cell mass biomarker. Diabetologia 2010; 53: 1406-1414.
37. Vats D, Wang H, Esterhazy D etal. Multimodal imaging of pancreatic beta cells in vivo by targeting transmembrane protein 27 (TMEM27). Diabetologia 2012; 55: 2407-2416.
38. Finne J, Finne U, Deagostini-Bazin H, Goridis C. Occurrence of alpha 2-8 linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys Res Commun 1983; 112: 482-487.
39. Bonfanti L. PSA-NCAM in mammalian structural plasticity and neurogenesis. Prog Neurobiol 2006; 80: 129-164.
40. Kiss JZ, Wang C, Olive S etal. Activity-dependent mobilization of the adhesion molecule polysialic NCAM to the cell surface of neurons and endocrine cells. EMBO J 1994; 13: 5284-5292.
41. Bernard-Kargar C, Kassis N, Berthault MF, Pralong W, Ktorza A. Sialylated form of the neural cell adhesion molecule (NCAM): a new tool for the identification and sorting of beta-cell subpopulations with different functional activity. Diabetes 2001; 50(Suppl. 1): S125-130.
42. Karaca M, Castel J, Tourrel-Cuzin C etal. Exploring functional beta-cell heterogeneity in vivo using PSA-NCAM as a specific marker. PLoS One 2009; 4: e5555.
43. Banerjee M, Otonkoski T. A simple two-step protocol for the purification of human pancreatic beta cells. Diabetologia 2009; 52: 621-625.
44. Reiner T, Thurber G, Gaglia J etal. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A 2011; 108: 12815-12820.
45. Brom M, Woliner-van der Weg W, Joosten L etal. Non-invasive quantification of the beta cell mass by SPECT with (111)In-labelled exendin. Diabetologia 2014; 57: 950-959.
46. Normandin MD, Petersen KF, Ding YS etal. In vivo imaging of endogenous pancreatic beta-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med 2012; 53: 908-916.
47. Roed SN, Wismann P, Underwood CR etal. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol 2014; 382: 938-949.
48. Ahnfelt-Ronne J, Hecksher-Sorensen J, Schaffer L, Madsen OD. A new view of the beta cell. Diabetologia 2012; 55: 2316-2318.
49. Secher A, Jelsing J, Baquero AF etal. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473-4488.
50. Keliher EJ, Reiner T, Thurber GM, Upadhyay R, Weissleder R. Efficient F-Labeling of synthetic exendin-4 analogues for imaging beta cells. Chem Open 2012; 1: 177-183.
51. Clardy SM, Keliher EJ, Mohan JF etal. Fluorescent exendin-4 derivatives for pancreatic beta-cell analysis. Bioconjug Chem 2014; 25: 171-177.
52. Wicki A, Wild D, Storch D etal. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007; 13: 3696-3705.
53. Brom M, Joosten L, Frielink C, Boerman O, Gotthardt M. (111)In-exendin uptake in the pancreas correlates with the beta cell mass and not with the alpha cell mass. Diabetes 2015; 64: 1324-1328.
54. Boerman OC, Gotthardt M. 18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster? Eur J Nucl Med Mol Imaging 2012; 39: 461-462.
55. Mukai E, Toyoda K, Kimura H etal. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun 2009; 389: 523-526.
56. Richards P, Parker HE, Adriaenssens AE etal. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014; 63: 1224-1233.
57. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405.
58. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008; 283: 11340-11347.
59. Berclaz C, Pache C, Bouwens A etal. Combined optical coherence and fluorescence microscopy to assess dynamics and specificity of pancreatic beta-cell tracers. Sci Rep 2015; 5: 10385.
60. Mikkola K, Yim CB, Fagerholm V etal. 64Cu- and 68Ga-labelled [Nle(14), Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 2014; 16: 255-263.
61. Selvaraju RK, Velikyan I, Johansson L etal. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med 2013; 54: 1458-1463.
62. Wang P, Yoo B, Yang J etal. GLP-1R-targeting magnetic nanoparticles for pancreatic islet imaging. Diabetes 2014; 63: 1465-1474.
63. Wild D, Behe M, Wicki A etal. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006; 47: 2025-2033.
64. Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med 2010; 363: 1289-1290.
65. Wu Z, Liu S, Hassink M etal. Development and evaluation of 18F-TTCO-Cys40-exendin-4: a PET probe for imaging transplanted islets. J Nucl Med 2013; 54: 244-251.
66. Antwi K, Fani M, Nicolas G etal. Localization of hidden insulinomas with 68Ga-DOTA-exendin-4 PET/CT: a pilot study. J Nucl Med 2015; 56: 1075-1078.
67. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010; 37: 1345-1355.
68. Kiesewetter DO, Gao H, Ma Y etal. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging 2012; 39: 463-473.
69. Mikkola K, Yim CB, Fagerholm V etal. Erratum to: Cu- and Ga-Labelled [Nle, Lys (Ahx-NODAGA)NH ]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 2013.
70. Vinet L, Lamprianou S, Babic A etal. Targeting GLP-1 receptors for repeated magnetic resonance imaging differentiates graded losses of pancreatic beta cells in mice. Diabetologia 2015; 58: 304-312.
71. Ladriere L, Malaisse-Lagae F, Malaisse WJ. Uptake of tritiated glibenclamide by endocrine and exocrine pancreas. Endocrine 2000; 12: 329-332.
72. Kaubisch N, Hammer R, Wollheim C, Renold AE, Offord RE. Specific receptors for sulfonylureas in brain and in a beta-cell tumor of the rat. Biochem Pharmacol 1982; 31: 1171-1174.
73. Guiot Y, Stevens M, Marhfour I etal. Morphological localisation of sulfonylurea receptor 1 in endocrine cells of human, mouse and rat pancreas. Diabetologia 2007; 50: 1889-1899.
74. Schneider S. Efforts to develop methods for in vivo evaluation of the native beta-cell mass. Diabetes Obes Metab 2008; 10(Suppl. 4): 109-118.
75. Carpentier JL, Sawano F, Ravazzola M, Malaisse WJ. Internalization of 3H-glibenclamide in pancreatic islet cells. Diabetologia 1986; 29: 259-261.
76. Schneider S, Ueberberg S, Korobeynikov A etal. Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regul Pept 2007; 139: 122-127.
77. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv Drug Deliv Rev 2012; 64: 571-588.
78. Stiriba SE, Frey H, Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew Chem Int Ed Engl 2002; 41: 1329-1334.
79. Anlauf M, Eissele R, Schafer MK etal. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 2003; 51: 1027-1040.
80. Raffo A, Hancock K, Polito T etal. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. J Endocrinol 2008; 198: 41-49.
81. Goland R, Freeby M, Parsey R etal. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009; 50: 382-389.
82. Kung MP, Hou C, Lieberman BP etal. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 2008; 49: 1171-1176.
83. Simpson NR, Souza F, Witkowski P etal. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol 2006; 33: 855-864.
84. Singhal T, Ding YS, Weinzimmer D etal. Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol 2011; 13: 973-984.
85. Tsao HH, Lin KJ, Juang JH etal. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol 2010; 37: 413-419.
86. Ludvigsen E. Somatostatin receptor expression and biological functions in endocrine pancreatic cells: review based on a doctoral thesis. Ups J Med Sci 2007; 112: 1-20.
87. Sako T, Hasegawa K, Nishimura M etal. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement. Biochem Biophys Res Commun 2013; 442: 79-84.
88. Sakano D, Shiraki N, Kikawa K etal. VMAT2 identified as a regulator of late-stage beta-cell differentiation. Nat Chem Biol 2014; 10: 141-148.
89. Fagerholm V, Mikkola KK, Ishizu T etal. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med 2010; 51: 1439-1446.
90. Hutton JC, Penn EJ, Peshavaria M. Low-molecular-weight constituents of isolated insulin-secretory granules. Bivalent cations, adenine nucleotides and inorganic phosphate. Biochem J 1983; 210: 297-305.
91. Vinkenborg JL, Nicolson TJ, Bellomo EA etal. Genetically encoded FRET sensors to monitor intracellular Zn2+ homeostasis. Nat Methods 2009; 6: 737-740.
92. Kristiansen LH, Rungby J, Sondergaard LG, Stoltenberg M, Danscher G. Autometallography allows ultrastructural monitoring of zinc in the endocrine pancreas. Histochem Cell Biol 2001; 115: 125-129.
93. Sondergaard LG, Stoltenberg M, Doering P, Flyvbjerg A, Rungby J. Zinc ions in the endocrine and exocrine pancreas of zinc deficient rats. Histol Histopathol 2006; 21: 619-625.
94. Esqueda AC, Lopez JA, Andreu-de-Riquer G etal. A new gadolinium-based MRI zinc sensor. J Am Chem Soc 2009; 131: 11387-11391.
95. Lubag AJ, De Leon-Rodriguez LM, Burgess SC, Sherry AD. Noninvasive MRI of beta-cell function using a Zn2+-responsive contrast agent. Proc Natl Acad Sci U S A 2011; 108: 18400-18405.
96. Stasiuk GJ, Minuzzi F, Sae-Heng M etal. Dual modal MR/fluorescent ratiometric zinc sensors towards pancreatic beta cell imaging. Chemistry 2015; 21: 5023-5033.
97. Stasiuk GJ, Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid on biomedical imaging. Chem Commun (Camb) 2013; 49: 2732-2746.
98. Mayo-Smith WW, Schima W, Saini S, Slater GJ, McFarland EG. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium. AJR Am J Roentgenol 1998; 170: 649-652.
99. Gimi B, Leoni L, Oberholzer J etal. Functional MR microimaging of pancreatic beta-cell activation. Cell Transplant 2006; 15: 195-203.
100. Antkowiak PF etal. Noninvasive assessment of pancreatic beta-cell function in vivo with manganese-enhanced magnetic resonance imaging. Am J Physiol Endocrinol Metab 2009; 296: E573-578.
101. Antkowiak PF, Stevens BK, Nunemaker CS, McDuffie M, Epstein FH. Manganese-enhanced magnetic resonance imaging detects declining pancreatic beta-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes. Diabetes 2013; 62: 44-48.
102. Lamprianou S, Immonen R, Nabuurs C etal. High-resolution magnetic resonance imaging quantitatively detects individual pancreatic islets. Diabetes 2011; 60: 2853-2860.
103. Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A 2004; 101: 12634-12639.
104. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med 2006; 12: 144-148.
105. Botsikas D, Terraz S, Vinet L etal. Pancreatic magnetic resonance imaging after manganese injection distinguishes type 2 diabetic and normoglycemic patients. Islets 2012; 4: 243-248.
106. Kavishwar A, Medarova Z, Moore A. Unique sphingomyelin patches are targets of a beta-cell-specific antibody. J Lipid Res 2011; 52: 1660-1671.
107. Ueberberg S, Meier JJ, Waengler C etal. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo. Diabetes 2009; 58: 2324-2334.
108. Eriksson O, Selvaraju RK, Johansson L etal. Quantitative imaging of serotonergic biosynthesis and degradation in the endocrine pancreas. J Nucl Med 2014; 55: 460-465.
109. Eriksson O, Espes D, Selvaraju RK etal. Positron emission tomography ligand [11C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes 2014; 63: 3428-3437.